Skip to main navigation Skip to search Skip to main content

Survivin and COX-2 expression in male breast carcinoma

  • Tallal Younis
  • , Kelly Dakin Haché
  • , Daniel Rayson
  • , Ron Dewar
  • , Samantha Gray
  • , Penny J. Barnes

Research output: Contribution to journalArticlepeer-review

Abstract

Male breast carcinoma (Male BC) is a distinct biological subtype of breast cancer. We previously reported an association between 5-year overall survival and strong intratumoral aromatase (ITA) expression in Male BC. In this study, we investigate survivin and COX-2 expression and their relationship to ITA. Clinical data were abstracted for all Male BC patients diagnosed between 1985 and 2005 in Nova Scotia, Canada. Archival tissues were retrieved for tissue microarray (TMA) and immunohistochemistry (IHC). Of 54 Male BCs identified, 39 cases had tissue available for IHC. Survivin expression was noted in 27 cases (69%); 12 nuclear and 26 cytoplasmic while strong COX-2 expression was observed in 14 cases (36%). Cytoplasmic survivin and COX-2 expressions were positively associated with ITA expression. However, survivin and COX-2 expression were not predictive of survival. Additional studies are needed to further elucidate the correlation between cytoplasmic survivin, COX-2 and ITA expression in Male BC considering their potential therapeutic implications.

Original languageEnglish
Pages (from-to)228-232
Number of pages5
JournalBreast
Volume18
Issue number4
DOIs
Publication statusPublished - Aug 2009
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Aromatase
  • COX-2
  • Male breast cancer
  • Prognostic markers
  • Survivin
  • Tissue microarray

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Survivin and COX-2 expression in male breast carcinoma'. Together they form a unique fingerprint.

Cite this